D-penicillamine-induced myasthenia gravis in rheumatoid arthritis. 1979

C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D010396 Penicillamine 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. Dimethylcysteine,Mercaptovaline,beta,beta-Dimethylcysteine,Copper Penicillaminate,Cuprenil,Cuprimine,D-3-Mercaptovaline,D-Penicillamine,Metalcaptase,D 3 Mercaptovaline,D Penicillamine,Penicillaminate, Copper,beta,beta Dimethylcysteine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
November 1977, Annals of internal medicine,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
June 1991, Ryumachi. [Rheumatism],
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
September 1990, Journal of clinical neuro-ophthalmology,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
December 1994, Clinical rheumatology,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
March 1991, Clinical immunology and immunopathology,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
October 2002, Neurosciences (Riyadh, Saudi Arabia),
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
January 1984, Duodecim; laaketieteellinen aikakauskirja,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
May 1994, Schweizerische medizinische Wochenschrift,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
December 1978, Nederlands tijdschrift voor geneeskunde,
C J Froelich, and F Hashimoto, and R P Searles, and A D Bankhurst
January 1981, Zeitschrift fur Rheumatologie,
Copied contents to your clipboard!